Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy (FAP)

NCT02175004 is registered in ClinicalTrials.gov with Ionis Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02175004
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02175004 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy (FAP)
Lead sponsor
Ionis Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
June 26, 2014
Completion date
January 7, 2021
Enrollment
135 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

amyloidosis, familial amyloid polyneuropathy, fap, transthyretin, ttr